How to buy Pfenex stock

Pfenex Inc is a biotechnology business based in the US. Pfenex shares (PFNX) are listed on the NYSE MKT and all prices are listed in US Dollars. Pfenex employs 88 staff and has a trailing 12-month revenue of around USD$41.1 million.

How to buy shares in Pfenex

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Pfenex. Find the stock by name or ticker symbol: PFNX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Pfenex reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Pfenex, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Pfenex. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Pfenex share price

Use our graph to track the performance of PFNX stocks over time.

Pfenex shares at a glance

• Key figures

Information last updated 2020-11-01.

52-week range	USD$5.26 - USD$14
50-day moving average	USD$12.7293
200-day moving average	USD$9.0912
Wall St. target price	USD$13
PE ratio	268.6667
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$0.03

Buy Pfenex shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Pfenex stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Pfenex Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Pfenex under- or over-valued?

Valuing Pfenex stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pfenex's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Pfenex's P/E ratio

Pfenex's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 269x. In other words, Pfenex shares trade at around 269x recent earnings.

Pfenex's EBITDA

Pfenex's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$2.6 million.

The EBITDA is a measure of a Pfenex's overall financial performance and is widely used to measure a its profitability.

Pfenex financials

Revenue TTM	USD$41.1 million
Gross profit TTM	USD$45.4 million
Return on assets TTM	-4.95%
Return on equity TTM	0%
Profit margin	-14.1%
Book value	$2.155
Market capitalisation	USD$437.3 million

TTM: trailing 12 months

Shorting Pfenex shares

There are currently 539,032 Pfenex shares held short by investors – that's known as Pfenex's "short interest". This figure is 31.3% down from 785,072 last month.

There are a few different ways that this level of interest in shorting Pfenex shares can be evaluated.

Pfenex's "short interest ratio" (SIR)

Pfenex's "short interest ratio" (SIR) is the quantity of Pfenex shares currently shorted divided by the average quantity of Pfenex shares traded daily (recently around 579604.30107527). Pfenex's SIR currently stands at 0.93. In other words for every 100,000 Pfenex shares traded daily on the market, roughly 930 shares are currently held short.

However Pfenex's short interest can also be evaluated against the total number of Pfenex shares, or, against the total number of tradable Pfenex shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pfenex's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Pfenex shares in existence, roughly 20 shares are currently held short) or 0.0184% of the tradable shares (for every 100,000 tradable Pfenex shares, roughly 18 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pfenex.

Find out more about how you can short Pfenex stock.

Pfenex share dividends

We're not expecting Pfenex to pay a dividend over the next 12 months.

Pfenex share price volatility

Over the last 12 months, Pfenex's shares have ranged in value from as little as $5.26 up to $14. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Pfenex's is 1.3233. This would suggest that Pfenex's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Pfenex overview

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidate include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis. The company also develops PF743, a recombinant crisantaspase; PF745, a recombinant crisantaspase with half-life extension technology; and PF810, a peptide based next generation therapeutic which is in preclinical development, as well as offers sparX-1 (PF753) and sparX-2 (PF754). In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California. As of September 29, 2020, Pfenex Inc. operates as a subsidiary of Ligand Pharmaceuticals Incorporated.

Frequently asked questions

• What percentage of Pfenex is owned by insiders or institutions?

  Currently 0.423% of Pfenex shares are held by insiders and 82.431% by institutions.

• How many people work for Pfenex?

  Latest data suggests 88 work at Pfenex.

• When does the fiscal year end for Pfenex?

  Pfenex's fiscal year ends in December.

• Where is Pfenex based?

  Pfenex's address is: 10790 Roselle Street, San Diego, CA, United States, 92121

• What is Pfenex's ISIN number?

  Pfenex's international securities identification number is: US7170711045

• What is Pfenex's CUSIP number?

  Pfenex's Committee on Uniform Securities Identification Procedures number is: 717071104